Insmed, Inc.
INSM
$93.39
-1.76%
Insmed, Inc. is a commercial-stage biopharmaceutical company organized around three therapeutic areas — Respiratory, Immunology and Inflammation, and Neuro and Other Rare — with two marketed products, Arikayce and Brinsupri, plus a clinical pipeline led by brensocatib (Brinsupri), TPIP, INS1148, and INS1201, and pre-clinical work spanning gene therapy, AI-driven protein engineering, and RNA end-joining. The company has evolved from a single-asset rare-disease player into a multi-product respiratory and inflammation platform, with brensocatib positioned as the key growth engine in bronchiectasis and Arikayce anchoring the commercial base in refractory nontuberculous mycobacterial lung disease. The current investor debate centers on the brensocatib launch trajectory and whether the company can convert a sharp revenue step-up into durable profitability, with the stock's steep 2026 drawdown reflecting skepticism about launch execution and cash burn rather than clinical doubt. Sentiment has been further shaped by the FDA's September 2026 acceptance of a priority-review filing to expand Arikayce's label, a potential incremental catalyst that analysts have largely greeted with unchanged Buy and Overweight ratings.…
INSM
Insmed, Inc.
$93.39
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold (with a speculative Buy bias for risk-tolerant investors). The core thesis is that Insmed's commercial inflection is real — 2,961% revenue growth, 84.2% gross margins, and positive EBITDA — but the stock's accelerating downtrend and 61.3x sales multiple mean the risk/reward is not yet compelling for a new position. The analyst consensus of strong_buy (mean 1.29) with a $197.00 average target implies +105% upside, anchoring the constructive view.
Supporting evidence: (1) Q2 2026 revenue of $425.49 million versus $107.42 million a year ago, with quarterly revenue roughly tripling in three quarters; (2) gross margin expansion from 73.9% to 84.2%; (3) net income improving from -$321.69 million to -$13.24 million year-over-year, with EBITDA turning positive at $14.16 million; (4) the $197.00 average target versus the $96.27 price, with even the $165.00 low target implying +71% upside. Against this, trailing free cash flow of -$837.67 million and a 61.3x PS ratio far above biotech norms cap the enthusiasm.
Key risks that could invalidate the thesis: launch durability as the brensocatib anniversary approaches, continued cash burn requiring dilution, and technical capitulation below the $90.39 low. The rating would upgrade to Buy if the stock forms a base above $112 (the broken July/September shelf) or if Q3 2026 revenue exceeds $450 million with FCF improving sequentially. It would downgrade to Sell if revenue decelerates below a $350 million quarterly run-rate or if a financing event occurs at a discount to market. Valuation verdict: the stock is fairly valued relative to its own compressed PS history (61.3x versus 54.5x in Q2 2026 and 213.9x in Q3 2025) but expensive relative to peers, leaving it dependent on flawless execution.
Sign up to view all
INSM 12-Month Price Forecast
The forward view is genuinely balanced: the commercial inflection is real and the sell-side consensus is uniformly constructive, but the stock's technical profile is a falling knife and the valuation leaves no room for error. The base case (45% probability) assumes revenue stabilizes near current levels and the stock bases in the $120–165 range, while the bull case (30%) requires continued launch acceleration toward the $197–243 targets. The bear case (25%) is a realistic capitulation scenario given the -56.54% max drawdown and persistent cash burn. I would upgrade to bullish if the stock reclaims $112 with improving FCF, and downgrade to bearish if it breaks below $90.39 or if Q3 revenue disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $196.14 and implied upside of +110.0% versus the current price.
Average Target
$196.14
0 analysts
Implied Upside
+110.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $243
Analyst target range
Coverage is deep and uniformly constructive: 22 analysts cover Insmed with a consensus recommendation of strong_buy and a recommendation mean of 1.29, and the average target price of $197.00 implies roughly +105% upside from the current $96.27. Consensus estimates call for EPS of $10.59 (range $8.90–$12.53) on average revenue of $6.32 billion (range $5.54–$7.21 billion), a forecast that assumes the brensocatib launch compounds well beyond the current $425 million quarterly run-rate. The consensus is unambiguously bullish, and the gap between the $197 target and the $96 price is one of the widest in large-cap biotech.
The target range of $165.00 to $243.00 is wide in absolute terms but entirely above the current price, signaling conviction rather than dispersion — even the low target implies +71% upside. The $243 high assumes full launch execution, label expansion for Arikayce following the FDA's priority-review acceptance, and pipeline optionality from TPIP and the immunology programs, while the $165 low still embeds substantial growth but less aggressive peak-sales assumptions or slower margin conversion. Institutional ratings show no downgrades in the recent record — Roth Capital, Truist, JP Morgan, Guggenheim, Evercore ISI, and Wells Fargo have all reiterated Buy/Overweight/Outperform between June and September 2026 — so the sell-side is holding its ground despite the 41% one-year decline, a divergence that either flags a significant mispricing or a consensus slow to mark down launch expectations.
Drowning in data?
Find the real signal!
Bulls vs Bears: INSM Investment Factors
The bull case rests on a genuine commercial inflection — 2,961% revenue growth, 84.2% gross margins, positive EBITDA, and a sell-side consensus that is uniformly constructive with a $197 average target implying +105% upside. The bear case rests on extreme valuation (61.3x sales), persistent cash burn (-$837.67 million trailing FCF), and a technical picture that shows no sign of bottoming. On balance, the bear evidence currently has stronger near-term force because the stock is in an accelerating downtrend with no base formation, and the valuation leaves no margin for error on launch execution. The single most important tension is whether the brensocatib run-rate proves durable as the launch anniversary approaches — if it does, the gap between the $96 price and $197 target closes rapidly; if it stalls, the 61x sales multiple has substantial room to compress further.
Bullish
- Revenue inflecting at unprecedented pace: Q2 2026 revenue of $425.49 million grew 2,961% year-over-year from $107.42 million, and quarterly revenue has roughly tripled from $142.34 million in Q3 2025 to $425.49 million in Q2 2026. This launch-driven curve, led by brensocatib alongside Arikayce, demonstrates genuine commercial traction rather than a one-off spike.
- Gross margin expanding with scale: Gross margin rose from 73.9% in Q2 2025 to 84.2% in Q2 2026, lifting gross profit to $358.27 million. This 10.3-point expansion reflects favorable product mix and operating leverage, providing a credible path to profitability as revenue scales.
- Analyst consensus overwhelmingly bullish: All 22 covering analysts rate the stock a strong buy (mean 1.29), with an average target of $197.00 implying +105% upside from $96.27. Even the lowest target of $165.00 implies +71% upside, and no downgrades were recorded between June and September 2026 despite the 41% one-year decline.
- Profitability inflection underway: Net income improved dramatically from -$321.69 million in Q2 2025 to -$13.24 million in Q2 2026, while EBITDA turned positive at $14.16 million and operating income narrowed to just -$1.55 million. The company is on the cusp of GAAP profitability.
Bearish
- Extreme valuation on any metric: The stock trades at 61.3x trailing sales and 18.7x EV/Sales, far above typical large-cap biotech multiples in the high-single to low-double digits. A forward PE of 120.7x on consensus EPS of $10.59 leaves no room for launch disappointment.
- Massive cash burn and dilution risk: Trailing free cash flow is -$837.67 million, with Q2 2026 operating cash flow of -$88.83 million and Q1 2026 FCF of -$226.22 million. The company funded growth partly through equity issuance ($28.01 million in Q2 2026, $860.50 million in Q2 2025), and interest expense runs at $20.27 million per quarter.
- Falling-knife technical profile: The stock is down 41.01% over one year and 45.65% year-to-date, sitting at just 4.8% of its 52-week range ($90.39–$212.75). One-month decline of 21.46% is nearly double the three-month decline of 11.12%, confirming accelerating downside momentum with relative strength of -22.68% versus SPY.
- Launch durability unproven: The revenue surge is launch-driven rather than steady compounding, and the investment case hinges on whether the $425 million quarterly run-rate holds as the brensocatib launch anniversary approaches. Consensus revenue of $6.32 billion assumes the launch compounds well beyond current levels, a high bar.
INSM Technical Analysis
Insmed is in a pronounced, sustained downtrend: the stock is down 41.01% over the past year and 45.65% year-to-date, with a maximum drawdown of -56.54% from its peak. At $96.27, the shares sit at roughly 4.8% of the 52-week range between the $90.39 low and $212.75 high — effectively pinned near the bottom of the range, which flags a falling-knife profile rather than a value entry until a base forms. The 52-week high of $212.75 is more than double the current price, underscoring how much momentum has been destroyed and how far overhead supply now sits.
Short-term momentum is deteriorating rather than stabilizing: the stock is down 21.46% over the past month and 11.12% over three months, meaning the one-month decline is nearly double the three-month decline and confirms acceleration to the downside. That contrasts violently with the broader market, with SPY up 1.22% over one month and 15.53% over one year, producing relative strength of -22.68% and -56.54% respectively — a persistent, widening underperformance that argues against mean-reversion buying. The tape shows two violent gaps (a drop from $137.09 to $105.00 in early May and a jump from $99.02 to $132.55 in early August), and the failure to hold the August spike above $130 has left a lower-high structure with the most recent close at $96.27, down 2.96% on the day.
Key technical levels are clear: support rests at the $90.39 52-week low, with the $94–$98 zone already being tested repeatedly in October, while resistance is layered at $108–$112 (the broken July/September shelf) and then $130–$135 (the August gap zone). A decisive break below $90.39 would signal capitulation and open a vacuum with no recent reference points, whereas reclaiming $112 would be the first evidence of a tradeable bottom. Volatility is a critical consideration: beta of 0.824 suggests lower systematic volatility than SPY, but that statistic badly understates the stock's idiosyncratic risk given a -56.54% drawdown, a short ratio of 6.46 days-to-cover, and average volume of roughly 2.4 million shares — position sizing should reflect event risk around launch metrics and pipeline readouts, not the beta figure.
Beta
0.82
0.82x market volatility
Max Drawdown
-56.5%
Largest decline past year
52-Week Range
$90-$213
Price range past year
Annual Return
-41.7%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -21.1% | -1.0% |
| 3m | -12.7% | +2.9% |
| 6m | -30.9% | +6.5% |
| 1y | -41.7% | +13.1% |
| ytd | -47.3% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Revenue is inflecting sharply: Q2 2026 revenue reached $425.49 million, up 2,961% year-over-year from $107.42 million in Q2 2025, driven by the brensocatib launch alongside Arikayce. The sequential trajectory is equally steep — $305.96 million in Q1 2026, $263.84 million in Q4 2025, and just $142.34 million in Q3 2025 — showing a business that has roughly tripled its quarterly top line in three quarters, with the single reportable segment contributing $406.19 million. This is a launch-driven growth curve rather than steady compounding, so the investment case now hinges on whether the run-rate holds as the launch anniversary approaches and consensus revenue of $6.32 billion is validated.
Profitability is at an inflection but not yet durable: Q2 2026 net income was -$13.24 million on a gross margin of 84.2%, a dramatic improvement from -$163.56 million in Q1 2026 and -$321.69 million in Q2 2025, with operating income of just -$1.55 million and EBITDA turning positive at $14.16 million. Gross margin has expanded from 73.9% in Q2 2025 to 84.2%, reflecting product mix and scale, but the operating expense base remains heavy — $210.03 million of R&D and $247.47 million of G&A in the quarter — leaving trailing net margin at -2.11% and operating margin at -194%. The path to profitability is credible given the margin structure, but it depends on revenue scaling faster than the roughly $460 million quarterly opex run-rate.
Balance-sheet and cash-flow quality is the weak link: trailing free cash flow is -$837.67 million, with Q2 2026 operating cash flow of -$88.83 million and capex of -$6.26 million, and Q1 2026 free cash flow of -$226.22 million. Liquidity is nonetheless solid, with a current ratio of 3.83, cash of $544.77 million at quarter-end, and debt-to-equity of 1.04, while ROE of -172.8% and ROA of -22.2% reflect a still-small equity base relative to losses. The company is funding growth partly through equity issuance ($28.01 million in Q2 2026, $860.50 million in Q2 2025) and carries meaningful interest expense of $20.27 million per quarter, so while near-term solvency is not in question, the negative FCF profile means dilution and financing risk remain live considerations.
Quarterly Revenue
$425486000.0B
2026-06
Revenue YoY Growth
+296.1%
YoY Comparison
Gross Margin
84.2%
Latest Quarter
Free Cash Flow
$-837669000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Because trailing net income is negative (EPS of -$0.03 and trailing PE of -27.15x), the PE ratio is not meaningful and I have selected the price-to-sales ratio as the primary metric, cross-checked against EV/Sales. The stock trades at 61.31x trailing sales and 18.68x EV/Sales, against a forward PE of 120.72x on consensus EPS of $10.59 — a gap that implies the market expects a dramatic earnings inflection as brensocatib scales, but the 61x sales multiple already discounts much of that recovery.
Relative to biotechnology norms, the valuation is extreme: a PS of 61.3x and a price-to-book of 50.3x sit far above typical large-cap biotech multiples in the high-single to low-double digits, and EV/EBITDA of -31.96x is negative and therefore uninformative. The premium is partly defensible — 84.2% gross margins, a tripling of quarterly revenue, and a differentiated respiratory franchise — but a 61x sales multiple on a company still burning roughly $840 million of trailing free cash flow leaves little room for launch disappointment, and the -1.80 PEG ratio underscores that earnings growth is not yet measurable against the price paid.
Historically, the stock's own PS band has compressed dramatically: PS was 213.9x in Q3 2025, 140.9x in Q4 2025, 115.2x in Q1 2026, and 54.5x in Q2 2026, so the current 61.3x sits near the low end of its recent range even as the absolute multiple remains elevated. That compression reflects revenue growth outrunning the share price rather than multiple expansion, and with the stock down 45.65% year-to-date against a 52-week high of $212.75, the market is de-rating the name — a setup that offers better value than a year ago but still requires flawless execution to justify the absolute multiple.
PE
-27.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's cash burn and dependence on continued revenue acceleration. Trailing free cash flow is -$837.67 million, with Q2 2026 operating cash flow of -$88.83 million and Q1 2026 FCF of -$226.22 million, while quarterly interest expense of $20.27 million adds a fixed burden. The roughly $460 million quarterly opex run-rate (R&D $210.03 million plus G&A $247.47 million) means profitability depends entirely on revenue scaling faster than costs, and the company has already relied on equity issuance ($860.50 million in Q2 2025, $28.01 million in Q2 2026), creating dilution risk if the launch slows. Liquidity is solid with a current ratio of 3.83 and $544.77 million in cash, so near-term solvency is not in question, but the negative FCF profile keeps financing risk live.
Market and competitive risks are dominated by valuation compression. At 61.3x trailing sales and 50.3x price-to-book, the stock trades at a steep premium to large-cap biotech norms in the high-single to low-double digits, and the forward PE of 120.7x on consensus EPS of $10.59 embeds a dramatic earnings inflection. The stock's beta of 0.824 suggests lower systematic volatility than SPY, but that statistic badly understates idiosyncratic risk given a -56.54% max drawdown and a short ratio of 6.46 days-to-cover. Competitive threats include emerging PAH competition referenced in recent coverage of LQDA's Yutrepia against UTHR and INSM, and any launch-share loss in bronchiectasis would hit the growth narrative directly.
Worst-case scenario: the brensocatib launch stalls as the anniversary approaches, consensus revenue of $6.32 billion proves unreachable, and the sell-side begins marking down targets from the current $165 low. Combined with continued cash burn forcing another equity raise, the stock could retest and break its 52-week low of $90.39, opening a vacuum with no recent reference points. From the current $96.27, a move to the $90.39 low represents roughly -6%, but a capitulation break toward the pre-launch trading range could imply a -35% to -45% drawdown, consistent with the stock's historical max drawdown of -56.54%.
FAQ
Ranked by severity: (1) Financial — trailing free cash flow of -$837.67 million and quarterly interest expense of $20.27 million create dilution risk if the launch slows; (2) Valuation — 61.3x trailing sales and 120.7x forward PE leave substantial room for multiple compression if growth decelerates; (3) Technical — the stock is in an accelerating downtrend (down 21.46% in one month) at 4.8% of its 52-week range, with a break below $90.39 opening a vacuum; (4) Competitive — emerging PAH competition and any bronchiectasis share loss would hit the growth narrative directly. The most severe is the financial risk, because a dilutive equity raise at a depressed price would compound the technical damage.
The 12-month forecast has three scenarios: bull case (30% probability, $197–243 target) requires brensocatib launch momentum to hold through the anniversary with quarterly revenue exceeding $500 million and Arikayce label expansion approval; base case (45% probability, $120–165 target) assumes revenue stabilizes near $400–450 million quarterly with improving free cash flow and the stock basing above $90.39; bear case (25% probability, $65–90 target) assumes launch stalling, a dilutive equity raise, and a break below the 52-week low. The base case is most likely, with the key assumption being that the brensocatib run-rate holds near current levels without further acceleration. The wide $165–243 analyst target range reflects conviction in the growth story but uncertainty on peak-sales assumptions.
On absolute metrics, INSM is expensive: 61.3x trailing sales, 50.3x price-to-book, and a forward PE of 120.7x on consensus EPS of $10.59, all far above typical large-cap biotech multiples in the high-single to low-double digits. However, relative to its own history, the multiple has compressed dramatically from 213.9x in Q3 2025 to 54.5x in Q2 2026, with the current 61.3x near the low end of that range. The market is paying a premium that implies it expects the brensocatib launch to compound well beyond the current $425 million quarterly run-rate toward consensus revenue of $6.32 billion. The verdict is fairly valued relative to its own compressed history but expensive relative to peers, leaving little room for launch disappointment.
From a risk/reward perspective, INSM offers an asymmetric setup only for investors who can tolerate near-term volatility: the $197.00 average analyst target implies +105% upside from $96.27, and even the $165.00 low target implies +71%. However, the stock is down 45.65% year-to-date and sits at just 4.8% of its 52-week range, with a one-month decline of 21.46% showing accelerating downside momentum. The biggest downside risk is a break below the $90.39 52-week low, which would open a vacuum toward the -35% to -45% drawdown range. For long-term, risk-tolerant investors with a 2–3 year horizon, the commercial inflection (2,961% revenue growth, 84.2% gross margins) makes it a speculative buy on stabilization; for conservative investors, waiting for a base above $112 is prudent.
INSM is best suited for long-term holding with a minimum 2–3 year horizon, given its commercial-stage growth profile, negative free cash flow, and zero dividend yield. The stock's beta of 0.824 understates its idiosyncratic volatility — a -56.54% max drawdown and a short ratio of 6.46 days-to-cover mean short-term trading carries event risk around launch metrics and pipeline readouts. Earnings visibility is improving (EBITDA turned positive at $14.16 million in Q2 2026) but not yet durable, so the investment case depends on the brensocatib launch anniversary and the Arikayce label expansion playing out over multiple quarters. Short-term traders should wait for a technical base above $112 before considering entry.